The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Open accessAbstract
Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Ferrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60237-3 · Cited by 2,464
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationInflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Cited by
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
“coli phagocytosis in a phosphatidylinositol-3-OH kinase (PI(3)K)- and scavenger receptor-dependent manner, and ALX/FPR2 is upregulated in patients with Crohn’s disease and enhances bacterial clearance(63).”
An inflammatory cytokine signature predicts COVID-19 severity and survival
Del Valle, D. M., Kim-Schulze, S., Huang, H.-H., Beckmann, N. D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T. H., Madduri, D., Stock, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1051-9 · Cited by 2,605
Mechanisms and Functions of Inflammasomes
Lamkanfi, M., & Dixit, V. M. (2014) · Cell · doi:10.1016/j.cell.2014.04.007 · Cited by 2,503
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945
“IL-1 affects virtually all cells and organs and is a major pathogenic mediator of autoinflammatory, autoimmune, infectious, and degenerative diseases (Dinarello, 2009, 2010; Dinarello et al., 2012; Gabay et al., 2010; Sims and Smith, 2010) (Table 2).”
InfluentialTargeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationRidker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Self-citationSpecialized pro-resolving mediators: endogenous regulators of infection and inflammation
Basil, M. C., & Levy, B. D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.4 · Cited by 791
Inflammasomes in neuroinflammatory and neurodegenerative diseases
Voet, S., Srinivasan, S., Lamkanfi, M., & van Loo, G. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810248 · Cited by 761
Limiting inflammation—the negative regulation of NF-κB and the NLRP3 inflammasome
Afonina, I. S., Zhong, Z., Karin, M., & Beyaert, R. (2017) · Nature Immunology · doi:10.1038/ni.3772 · Cited by 759
Channelling inflammation: gasdermins in physiology and disease
Liu, X., Xia, S., Zhang, Z., Wu, H., & Lieberman, J. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00154-z · Cited by 751
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., Wang, A., Tao, J., Wang, C., Liu, Q., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171419 · Cited by 748
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Self-citationPietras, E. M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L. V., Zhang, S., Lakshminarasimhan, R., Chin, C. P., Techner, J.-M., Will, B., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3346 · Cited by 689
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
The role of interleukin-1 in general pathology
Kaneko, N., Kurata, M., Yamamoto, T., Morikawa, S., & Masumoto, J. (2019) · Inflammation and Regeneration · doi:10.1186/s41232-019-0101-5 · Cited by 617
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., Carta, S., Tengesdal, I., Nemkov, T., D’Alessandro, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716095115 · Cited by 574
Self-citationSabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
The Warburg effect then and now: From cancer to inflammatory diseases
Palsson‐McDermott, E. M., & O'Neill, L. A. J. (2013) · BioEssays · doi:10.1002/bies.201300084 · Cited by 537
Regulation of Osteoclast Differentiation by Cytokine Networks
Amarasekara, D. S., Yun, H., Kim, S., Lee, N., Kim, H., & Rho, J. (2018) · Immune Network · doi:10.4110/in.2018.18.e8 · Cited by 518
The diverse role of RIP kinases in necroptosis and inflammation
Silke, J., Rickard, J. A., & Gerlic, M. (2015) · Nature Immunology · doi:10.1038/ni.3206 · Cited by 514
Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme
Afonina, I. S., Müller, C., Martin, S. J., & Beyaert, R. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.003 · Cited by 490
NLRP3 inflammasome in neurological diseases, from functions to therapies
Song, L., Pei, L., Yao, S., Wu, Y., & Shang, Y. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00063 · Cited by 467
Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases
Spite, M., Clària, J., & Serhan, C. N. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.006 · Cited by 464
Mechanisms regulating PD-L1 expression on tumor and immune cells
Chen, S., Crabill, G. A., Pritchard, T. S., McMiller, T. L., Wei, P., Pardoll, D. M., Pan, F., & Topalian, S. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0770-2 · Cited by 459
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
Host and Environmental Factors Influencing Individual Human Cytokine Responses
ter Horst, R., Jaeger, M., Smeekens, S. P., Oosting, M., Swertz, M. A., Li, Y., Kumar, V., Diavatopoulos, D. A., Jansen, A. F. M., Lemmers, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.018 · Cited by 453
Self-citationTrained immunity — basic concepts and contributions to immunopathology
Ochando, J., Mulder, W. J. M., Madsen, J. C., Netea, M. G., & Duivenvoorden, R. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00633-5 · Cited by 453
Palomo, J., Dietrich, D., Martin, P., Palmer, G., & Gabay, C. (2015) · Cytokine · doi:10.1016/j.cyto.2015.06.017 · Cited by 447
The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease
Wang, S., Yuan, Y.-H., Chen, N.-H., & Wang, H.-B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.019 · Cited by 444
Therapeutic targeting of trained immunity
Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A., & Netea, M. G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0025-4 · Cited by 443
Daniels, M. J. D., Rivers-Auty, J., Schilling, T., Spencer, N. G., Watremez, W., Fasolino, V., Booth, S. J., White, C. S., Baldwin, A. G., Freeman, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12504 · Cited by 442
Cell death in the gut epithelium and implications for chronic inflammation
Patankar, J. V., & Becker, C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0326-4 · Cited by 411
Emerging cytokine networks in colorectal cancer
West, N. R., McCuaig, S., Franchini, F., & Powrie, F. (2015) · Nature Reviews Immunology · doi:10.1038/nri3896 · Cited by 396
Abbate, A., Van Tassell, B. W., Biondi-Zoccai, G., Kontos, M. C., Grizzard, J. D., Spillman, D. W., Oddi, C., Roberts, C. S., Melchior, R. D., Mueller, G. H., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.287 · Cited by 393
Self-citationTargeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives
Doyle, S., Ozaki, E., & Campbell, M. (2015) · Journal of Inflammation Research · doi:10.2147/jir.s51250 · Cited by 380
de Zoete, M. R., Palm, N. W., Zhu, S., & Flavell, R. A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016287 · Cited by 379
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Linden, J., Koch-Nolte, F., & Dahl, G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052406 · Cited by 377
IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376
Inflammasome signaling and regulation of interleukin-1 family cytokines
Chan, A. H., & Schroder, K. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190314 · Cited by 373
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Self-citationConstitutive immune mechanisms: mediators of host defence and immune regulation
Paludan, S. R., Pradeu, T., Masters, S. L., & Mogensen, T. H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0391-5 · Cited by 362
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
Klein, A. L., Imazio, M., Cremer, P., Brucato, A., Abbate, A., Fang, F., Insalaco, A., LeWinter, M., Lewis, B. S., Lin, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2027892 · Cited by 358
Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356
Morton, A. C., Rothman, A. M. K., Greenwood, J. P., Gunn, J., Chase, A., Clarke, B., Hall, A. S., Fox, K., Foley, C., Banya, W., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu272 · Cited by 353
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain
Sisignano, M., Baron, R., Scholich, K., & Geisslinger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.211 · Cited by 344
Inflammasome-independent regulation of IL-1-family cytokines
Netea, M. G., van de Veerdonk, F. L., van der Meer, J. W. M., Dinarello, C. A., & Joosten, L. A. B. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112306 · Cited by 326
Self-citationIL-1 Blockade in Autoinflammatory Syndromes
Jesus, A. A., & Goldbach-Mansky, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-150641 · Cited by 326
Tilg, H., Moschen, A. R., & Szabo, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
de Luca, A., Smeekens, S. P., Casagrande, A., Iannitti, R., Conway, K. L., Gresnigt, M. S., Begun, J., Plantinga, T. S., Joosten, L. A. B., van der Meer, J. W. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322831111 · Cited by 313
“Anakinra is relatively safe (39), its short t1/2 provides an exit in the event of an infectious process, and blocking IL-1 deserves a trial in a larger cohort of patients with CGD.”
BackgroundSelf-citationAsgari, E., Le Friec, G., Yamamoto, H., Perucha, E., Sacks, S. S., Köhl, J., Cook, H. T., & Kemper, C. (2013) · Blood · doi:10.1182/blood-2013-05-502229 · Cited by 310
The IL-1β phenomena in neuroinflammatory diseases
Mendiola, A. S., & Cardona, A. E. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1732-9 · Cited by 303
Targeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
The IL-1 cytokine family and its role in inflammation and fibrosis in the lung
Borthwick, L. A. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0559-z · Cited by 294
Structural Basis of IL-1 Family Cytokine Signaling
Fields, J. K., Günther, S., & Sundberg, E. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01412 · Cited by 299
Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
Cheng, R., Wu, Z., Li, M., Shao, M., & Hu, T. (2020) · International Journal of Oral Science · doi:10.1038/s41368-019-0068-8 · Cited by 298
Ilott, N. E., Heward, J. A., Roux, B., Tsitsiou, E., Fenwick, P. S., Lenzi, L., Goodhead, I., Hertz-Fowler, C., Heger, A., Hall, N., et al. (2014) · Nature Communications · doi:10.1038/ncomms4979 · Cited by 293
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Self-citationLDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications
Zeng, C., Wang, R., & Tan, H. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.33568 · Cited by 283
Inflammasome-dependent IL-1β release depends upon membrane permeabilisation
Martín-Sánchez, F., Diamond, C., Zeitler, M., Gomez, A. I., Baroja-Mazo, A., Bagnall, J., Spiller, D., White, M., Daniels, M. J. D., Mortellaro, A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.176 · Cited by 279
Caspase-1: The inflammasome and beyond
Sollberger, G., Strittmatter, G. E., Garstkiewicz, M., Sand, J., & Beer, H.-D. (2014) · Innate Immunity · doi:10.1177/1753425913484374 · Cited by 275
Sterile inflammation and pregnancy complications: a review
Nadeau-Vallée, M., Obari, D., Palacios, J., Brien, M.-È., Duval, C., Chemtob, S., & Girard, S. (2016) · Reproduction · doi:10.1530/rep-16-0453 · Cited by 275
Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery
Zakkar, M., Ascione, R., James, A. F., Angelini, G. D., & Suleiman, M. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.009 · Cited by 274
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
“IL-1 driven inflammation is known to contribute to tumor development and invasiveness (Dinarello et al., 2012; Lee et al., 2015).”
BackgroundThe central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273
Febrile infection‐related epilepsy syndrome treated with anakinra
Kenney‐Jung, D. L., Vezzani, A., Kahoud, R. J., LaFrance‐Corey, R. G., Ho, M., Muskardin, T. W., Wirrell, E. C., Howe, C. L., & Payne, E. T. (2016) · Annals of Neurology · doi:10.1002/ana.24806 · Cited by 265
IL-1 receptor 2 (IL-1R2) and its role in immune regulation
Peters, V. A., Joesting, J. J., & Freund, G. G. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.006 · Cited by 264
Marchetti, C., Chojnacki, J., Toldo, S., Mezzaroma, E., Tranchida, N., Rose, S. W., Federici, M., Van Tassell, B. W., Zhang, S., & Abbate, A. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000053 · Cited by 264
Caforio, A. L. P., Adler, Y., Agostini, C., Allanore, Y., Anastasakis, A., Arad, M., Böhm, M., Charron, P., Elliott, P. M., Eriksson, U., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx321 · Cited by 263
Immune Mechanisms in Heart Failure
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.942 · Cited by 262
Level of IL-6, TNF, and IL-1β and age-related diseases: a systematic review and meta-analysis
Tylutka, A., Walas, Ł., & Zembron-Lacny, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330386 · Cited by 262
Human TLR10 is an anti-inflammatory pattern-recognition receptor
Oosting, M., Cheng, S.-C., Bolscher, J. M., Vestering-Stenger, R., Plantinga, T. S., Verschueren, I. C., Arts, P., Garritsen, A., van Eenennaam, H., Sturm, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410293111 · Cited by 260
Self-citationAnti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase
Jonigk, D., Al-Omari, M., Maegel, L., Müller, M., Izykowski, N., Hong, J., Hong, K., Kim, S.-H., Dorsch, M., Mahadeva, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309648110 · Cited by 258
Self-citationBallak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., & van Diepen, J. A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.005 · Cited by 255
Self-citationTargeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction
Sager, H. B., Heidt, T., Hulsmans, M., Dutta, P., Courties, G., Sebas, M., Wojtkiewicz, G. R., Tricot, B., Iwamoto, Y., Sun, Y., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016160 · Cited by 253
Saxena, A., Chen, W., Su, Y., Rai, V., Uche, O. U., Li, N., & Frangogiannis, N. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300725 · Cited by 252
Sleep duration, cardiovascular disease, and proinflammatory biomarkers
Grandner, M., Sands-Lincoln, Pak, & Garland (2013) · Nature and Science of Sleep · doi:10.2147/nss.s31063 · Cited by 246
Duffy, D., Rouilly, V., Libri, V., Hasan, M., Beitz, B., David, M., Urrutia, A., Bisiaux, A., LaBrie, S. T., Dubois, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.002 · Cited by 242
Biologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
The immunomodulating role of exercise in metabolic disease
Lancaster, G. I., & Febbraio, M. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.02.008 · Cited by 193
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
Dynamic mapping of proteome trafficking within and between living cells by TransitID
Qin, W., Cheah, J. S., Xu, C., Messing, J., Freibaum, B. D., Boeynaems, S., Taylor, J. P., Udeshi, N. D., Carr, S. A., & Ting, A. Y. (2023) · Cell · doi:10.1016/j.cell.2023.05.044 · Cited by 160
Rider, P., Carmi, Y., Voronov, E., & Apte, R. N. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.005 · Cited by 155
Gresnigt, M. S., Bozza, S., Becker, K. L., Joosten, L. A. B., Abdollahi-Roodsaz, S., van der Berg, W. B., Dinarello, C. A., Netea, M. G., Fontaine, T., De Luca, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003936 · Cited by 142
Self-citationSelective killing of candidate AML stem cells by antibody targeting of IL1RAP
Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood · doi:10.1182/blood-2012-09-458935 · Cited by 127
Zhao, Z., Wang, Y., Zhou, R., Li, Y., Gao, Y., Tu, D., Wilson, B., Song, S., Feng, J., Hong, J.-S., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1728-5 · Cited by 109
Hofbauer, D., Mougiakakos, D., Broggini, L., Zaiss, M., Büttner-Herold, M., Bach, C., Spriewald, B., Neumann, F., Bisht, S., Nolting, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.002 · Cited by 100
Metadata
- Authors
- Dinarello, C. A., Simon, A., & van der Meer, J. W. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-08
- Volume
- 11
- Issue
- 8
- Pages
- 633-652
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2108373994
- Cited by
- 1,768
- References
- 189
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.